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Summary: Systemic exposure to isoniazid and rifampicin correlates with bacillary clearance from 
sputum and bacillary clearance from sputum correlates with tuberculosis treatment outcome. 
These findings show the potential of longitudinal PKPD biomarkers for trial design and clinical 
decision making. 
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Abstract 
Background: This study aims to explore relationships between baseline demographic covariates, 
plasma antibiotic exposure, sputum bacillary load and clinical outcome data to help improve future 
TB treatment response predictions. 
Methods: Data were available from a longitudinal cohort study in Malawian drug sensitive TB 
patients on standard therapy, including steady-state plasma antibiotic exposure (154 patients), 
sputum bacillary load (102 patients), final outcome (87 patients) and clinical details. Population 
pharmacokinetic and pharmacokinetic-pharmacodynamic models were developed in the software 
package 𝑁𝑂𝑁𝑀𝐸𝑀. Outcome data were analysed using univariate logistic regression and Cox 
proportional hazard models in 𝑅, a free software for statistical computing. 
Results: Higher isoniazid exposure correlated with increased bacillary killing in sputum (p<0.01). 
Bacillary killing in sputum remained fast, with later progression to biphasic decline, in patients with 
higher rifampicin AUC0-24 (p<0.01). Serial Sputum Colony Counting negativity at month 2 (P<0.05), 
isoniazid CMAX (p<0.05), isoniazid CMAX/MIC (p<0.01) and isoniazid AUC0-24/MIC (p<0.01) 
correlated with treatment success but not with remaining free of TB. Slower bacillary killing 
(P<0.05) and earlier progression to biphasic bacillary decline (p<0.01) both correlate with treatment 
failure. Post-treatment recurrence only correlated with slower bacillary killing (P<0.05). 
Conclusions: Patterns of early bacillary clearance matter. Static measurements such as month 2 
sputum conversion and pharmacokinetic parameters such as CMAX/MIC and AUC0-24/MIC were 
predictive of treatment failure, but modelling of quantitative longitudinal data was required to 
assess the risk of recurrence. Pooled individual patient data analyses from larger datasets are 
needed to confirm these findings. 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article-abstract/doi/10.1093/ofid/ofaa218/5854288 by U
niversity of Liverpool user on 22 June 2020
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
Introduction 
Tuberculosis (TB) caused an estimated 1.2 million deaths worldwide from 10 million clinical cases 
in 2018.1 There is an urgent need for short, effective treatments. The current standard treatment of 
drug-sensitive TB remains long at six months and efforts to shorten standard TB treatment have 
been unsuccessful.2–4 Potent early anti-bacterial activity from short-course moxifloxacin-containing 
regimens did not translate into non-inferior treatment success rates compared to standard of care 
regimens in Phase III clinical trials.2 Ongoing efforts to tackle the problem include new trials of 
novel drug combinations (e.g. SimpliciTB, ClinicalTrials.gov Identifier: NCT03338621) and 
consideration of treatment individualisation or stratification, targeting shorter treatment to the 
patients who are most likely to be cured (e.g. TRUNCATE-TB, ClinicalTrials.gov Identifier: 
NCT03474198). Both approaches would benefit from a biomarker that predicts final treatment 
outcome during the early weeks of treatment. This currently does not exist and treatment 
stratification is currently focused on baseline measurements. Progress would be accelerated by 
improved understanding of relationships between antibiotic exposure for individual antimicrobial 
drugs, serial quantitative bacterial load measurements and clinical outcomes. Statistical and 
mathematical modelling has already enhanced our understanding of the aforementioned 
relationships.5–7 Several pharmacodynamic (PD) and pharmacokinetic-pharmacodynamic (PKPD) 
models have been developed to study the correlation between drug concentrations and the 
bactericidal effect of treatment.6–11 These models enable prediction of early drug effect, but 
analyses become difficult when bacterial loads fall below the limit of quantification. Month two and 
month three culture sputum culture conversion have been proposed as moderately good predictors 
of long-term treatment failure or relapse risk between treatment arms of early phase clinical trials.5 
However, the predictive value of culture conversion is weak for individual patient care,12 hampering 
robust translation to drug development and clinical programmes. 
Our overarching hypothesis is that integrating models describing correlations between individual 
antibiotic exposure and early anti-bacterial effect with models relating early anti-bacterial effect to 
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/advance-article-abstract/doi/10.1093/ofid/ofaa218/5854288 by U
niversity of Liverpool user on 22 June 2020
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
treatment outcome will improve our understanding of treatment response and contribute to 
improved outcome predictions. The aim of this study was to explore predictors for treatment 
outcome using baseline demographic, steady-state plasma antibiotic exposure and serial sputum 
bacillary load data from drug sensitive TB patients. Specific goals were to 1.) fit pharmacokinetic 
(PK) models to concentration-time data for each of the first-line anti-tuberculosis drugs, 2.) fit a 
population PKPD model to sputum bacterial load-time data, and 3.) explore associations between 
early bacillary clearance from sputum and treatment success and recurrence of TB. 
Materials and methods 
Study population and study design 
Data from patients recruited to a longitudinal cohort study of clinical, pharmacological, and 
bacteriological responses to TB therapy conducted in Queen Elizabeth Central Hospital in 
Blantyre, Malawi were analysed. The Liverpool School of Tropical Medicine and the College of 
Medicine Research Ethics Committee, University of Malawi gave ethical approval for this study. 
Longitudinal PD and outcome data from this patient cohort has been published.13 The current study 
extends that work with PKPD analyses. 
Consenting adults aged 16-65 years with sputum smear-positive pulmonary TB were eligible. 
Exclusion criteria included haemoglobin<6g/dL, creatinine>177 𝜇mol/l, total bilirubin>51 𝜇mol/l, 
alanine transaminase >200 IU/l, clinical status suggestive of imminent mortality, pregnancy, prior 
TB treatment within five years, concurrent corticosteroid therapy or baseline resistance to 
rifampicin and isoniazid using the Genotype MTBDRplus 2.0 line probe assay (LPA, Hain Life 
Sciences). Patient characteristics have been reported previously.13 Alcohol consumption (any beer 
or spirits) and smoking were reported as binary covariates based on practice at the time of study 
recruitment. Percentage of abnormal lung-field observed on baseline chest radiographs (CXR) was 
assessed by consensus of two independent readers. On binary variables (e.g. presence / absence 
of cavities): the reviewers met to reach consensus on any discrepancies. On continuous variables 
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(e.g. % lung-field affected), an average of the two scores was taken. Participants received daily 
Fixed Dose Combination (FDC) tablets containing a standard first-line WHO-approved regimen 
according to the Malawi Ministry of Health National TB Control Programme Manual 6th Edition 
2007. The detail is as follows: For the Intensive Phase of therapy fixed dose RZHE tablets 
(rifampicin 150mg, isoniazid 75mg, pyrazinamide 400mg, ethambutol 275mg) were used. For the 
Continuation Phase, RH tablets (rifampicin 150mg, isoniazid 75mg) were used. Weight bands for 
both phases were: 30-37kg - 2 tablets, 37-54kg - 3 tablets, 54-74kg - 4 tablets, $$74kg - 5 tablets. 
Adherence was monitored by direct questioning and pill counts. All patients had point of care HIV 
serology. Anti-retroviral therapy (ART) was provided per national protocols. 
Clinical endpoint definitions 
An endpoint of stable cure was reported for patients who were clinically well with two consecutive 
negative sputum cultures by the End of Treatment (EOT) and no TB recurrence in the subsequent 
12 months. Treatment failure was reported for patients with positive sputum culture at EOT. TB 
recurrence was reported for patients who appeared to be cured at EOT but re-presented with TB 
disease, i.e. reinfection or relapse, in the next 12 months. The LPA was repeated on positive EOT 
or post-treatment Mycobacterium tuberculosis (Mtb) isolates from treatment failures or TB 
recurrences respectively. 
Bacterial load measurement 
Patients had overnight sputum samples collected on day 0, 2, 4, 7, 14, 28, 49, and 56 of treatment. 
Auramine-phenol microscopy was done on direct and concentrated sputum smears at all time 
points. Two 1ml aliquots were used for sputum bacillary load measurement on solid (Serial Sputum 
Colony Counting [SSCC]) and liquid (Mycobacterial Growth Indicator Tube [MGIT]) culture. All 
patients submitted spot sputum samples after 5 months of therapy (EOT samples) to assess 
bacteriological cure. Those with ongoing or recurrent symptoms submitted post treatment samples 
to test for relapse. Standard bacteriological methods for SSCC (results reported as log10 colony 
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forming units (CFU)/ml) and MGIT (results reported as days-to-positivity but analysed in this paper 
as a binary positive/negative result at month 1 and 2) were as previously described.13 Only patients 
who contributed at least two bacterial load measurements could be included in PKPD models, as a 
bacterial clearance rate cannot be calculated from a single measurement. 
Minimum Inhibitory Concentration (MIC) assays 
Mtb isolates from baseline sputum cultures of all patients were stored at -70oC for bioanalysis on 
UKMYC sensititre plates (Thermofisher). Plates for this project were custom-configured by the 
manufacturer; the wells contained dry microdilutions of lyophilised antibiotics across concentrations 
which allowed careful MIC titration within the drug-susceptible range (two antibiotic-free control 
wells; doubling dilutions from 16-0.015 mg/L for rifampicin and isoniazid; doubling dilutions from 8-
0.25mg/L for ethambutol). 
Mtb Isolates were revived in Middlebrook 7H9 broth, then sub-cultured onto Middlebrook 7H11 
agar. Colonies were emulsified in 0.2% saline-tween with glass beads, and vortexed for 30 
seconds. Turbidity was adjusted to 0.5 McFarland Standard. 100 ul from each suspension were 
transferred into 11ml Middlebrook 7H9 broth, supplemented with oleic acid-albumin-dextrose-
catalase, to give an inoculum of 105 cfu/ml. 100 ul of this material from each isolate were 
inoculated, in duplicate, into plate wells covering all concentrations of all drugs. Plates were 
covered with permanent plastic seals and incubated at 37°C in 5% CO2. Plates were checked for 
contamination at 24 and 48 hours, then monitored at 10, 14, and 21 days. Results were read when 
growth was clearly visible in the antibiotic-free control wells. For each antibiotic, the lowest 
concentration with no visible growth was considered to be the MIC. Each plate was read by two 
independent readers. The MIC result recorded by the first reader was the test result. The second 
reader’s result was used to assess inter-reader agreement. 
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Antibiotic plasma concentration measurement 
Blood collections to measure steady-state isoniazid, rifampicin, pyrazinamide, and ethambutol 
concentrations were undertaken on day 14 or 21 of treatment. Patients attended the study clinic 
after an overnight fast at 07:30 hours. Samples were collected pre-dose, then 2 and 6 hours after 
medications. To allow patients to return home before nightfall, 6 hours post-dose was the latest 
sampling timepoint. Similar field-based clinical studies in southern Africa14 have deployed similar 
collection strategies. Plasma was separated by centrifugation and stored at -70oC until batched 
analysis. Rifampicin, isoniazid and ethambutol concentrations were determined using previously 
published liquid chromatographic/tandem mass spectrometry methods15,16 with appropriate internal 
standards validated to internationally recognised acceptance criteria as previously described.17 
Pyrazinamide concentrations were measured by HPLC using an Ultraviolet visible (UV-Vis) 
absorption detector. 
Pharmacokinetics 
Population pharmacokinetic models were developed using the Stochastic Approximation 
Expectation Method in the Fortran based software package NONMEM18 with a g95 Fortran 
compiler. Empirical Bayes AUC0-24 and CMAX estimates were derived for each patient and evaluated 
as predictors on bacillary clearance and treatment outcome. Details on pharmacokinetic model 
building can be found in the supplementary materials. 
Pharmacokinetics-pharmacodynamics 
Bacillary clearance from sputum can be captured using mono-phasic (Fig. 2, profile A) or bi-phasic 
models (Fig. 2, profile B and C). Our PKPD model used the parameter LAM to represent the slope 
of a monophasic bacterial decay curve or the first phase of a bi-phasic bacterial decay curve (Fig. 
2). For bi-phasic clearance the magnitude of decline in bacterial clearance was parameterised in 
this model by BETA and the time it takes to switch from fast killing to slow killing was 
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parameterised using the parameter t1/2 (Fig. 2). Details on PKPD model building can be found in 
the supplementary materials. 
P-values of 0.05 and 0.01 were used as cut-offs in the forward inclusion and backward elimination 
step of stepwise covariate model building. Covariates, to be evaluated on PKPD model 
parameters, were selected based on physiological plausibility and a correlation matrix with post-
hoc pharmacodynamic parameter estimates from the baseline model. The following parameters 
were consequently evaluated on baseline sputum bacillary load using an exponential relationship: 
age, body mass index (BMI), percentage of abnormal lung-field on CXR , and baseline bilirubin 
and creatinine concentrations. Isoniazid and rifampicin AUC0-24 and CMAX, BMI, baseline serum 
bilirubin and creatinine concentrations, HIV infection, current alcohol consumption and treatment 
adherence were evaluated on 𝜃𝐿𝐴𝑀 . AUC0-24 and CMAX of all four study drugs, age, BMI, percentage 
of abnormal lung-field on CXR, baseline bilirubin and baseline creatinine were evaluated on 𝜃𝑇1/2. 
AUC0-24 and CMAX of all four study drugs, age, BMI, percentage of abnormal lung-field on CXR, 
baseline bilirubin and creatinine concentrations were evaluated on 𝜃𝛽. MIC adjusted isoniazid and 
rifampicin AUC0-24 were evaluated on a subset of patients with available MIC data. AUC0-24/MIC 
was substituted for AUC0-24 equivalents in the final model and statistical significance was tested 
using a back-ward elimination approach. 
Empirical Bayes estimates for parameters LAM, BETA and T1/2 were derived for each patient and 
evaluated as predictors for treatment outcome. 
Study outcome 
Univariate logistic regression was used to investigate the role of clinical, pharmacokinetic and 
bacteriological factors as explanatory variables to predict stable cure and failure. A Cox-
proportional hazard model was used to investigate the role of clinical, pharmacokinetic and 
bacteriological factors as explanatory variables to predict recurrence amongst patients that had 
stable cure at EOT. Bacteriological factors were categorised as static measurements (e.g. sputum 
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smear and culture [SSCC or MGIT] conversion to negative at end of month one or two) or dynamic 
PKPD model derived parameters (e.g. LAM, T1/2 and BETA). Correlations between MIC adjusted 
isoniazid, rifampicin or ethambutol exposure (CMAX or AUC0-24) and outcome (failure or recurrence) 
were evaluated on patients with available MIC data. 
Results 
Plasma antibiotic concentration-time data were available from 154 patients (Table 1). 52 patients 
contributed fewer than 2 bacterial load samples leaving 102 for the PKPD analysis. Seven patients 
withdrew from the study before reaching EOT, 3 upon the patients’ request, 3 according protocol 
and 1 patient was lost to follow-up, leaving 95 patients for the treatment failure outcome analysis. 
Five patients failed treatment. Amongst the 90 successfully treated patients one withdrew from the 
study immediately after EOT and consequently did not participate in the follow-up phase leaving 89 
patients for recurrence outcome analysis. Amongst these patients 78 remained TB free and 4 had 
recurrent infection. Seven patients were censored as 5 were lost to follow-up, and 2 died of non-
tuberculous causes during post-treatment follow-up (S1 Fig.). 
87% of patients reported no missed treatment doses, 9% reported 1-2 missed doses and 7/143 
(5%) reported ≥3 missed doses. All patients had rifampicin and isoniazid susceptible TB at 
baseline. MICs for isoniazid, rifampicin and ethambutol, available from 47 patients with clinical 
outcome data, confirmed that the Mtb isolates were extremely sensitive to the antibiotics used 
(Table 1). Of the 5 treatment failures, one had isoniazid and rifampicin resistance detected on LPA 
at EOT, suggesting acquisition of multi drug resistant (MDR-)TB during therapy. Of the four TB 
recurrences, one had isoniazid mono-resistance detected at symptomatic re-presentation, 
suggesting either acquisition of resistance on treatment or re-infection with an isoniazid mono-
resistant strain. A baseline profile of the study cohort is shown in Table 1. 
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Pharmacokinetics 
Visual predictive checks (VPCs) and goodness of fit diagnostics (GOFs) for the isoniazid, 
rifampicin, pyrazinamide and ethambutol models showed adequate predictive performance (Fig. 1; 
S2 Fig.; S3 Fig.; S1 Table). Model derived median CMAX estimates and ranges for the study cohort 
were: isoniazid, 3.24 (2.19-5.50) mg/l; rifampicin, 4.35 (2.30-12.30) mg/l; pyrazinamide, 40 (25-63) 
mg/l; and ethambutol, 2.30 (1.43-4.40) mg/l. Median AUC0-24 estimates and ranges were: isoniazid, 
18.83 (6.97-71.20) hxmg/l rifampicin, 29.10 (14.50-119.00) hxmg/l; pyrazinamide, 419 (210-2014) 
hxmg/l; and ethambutol 18.50 (12.80-38.50) hxmg/l. 
Pharmacokinetics-pharmacodynamics 
Isoniazid AUC0-24 at steady state and baseline serum bilirubin concentrations positively correlated 
(p < 0.01) in an exponential relation with LAM (Fig. 2) in the PKPD model (Fig. 3; S4 Fig.; S5 Fig.), 
resulting in a steeper bacillary kill-curve in sputum with higher isoniazid exposures and baseline 
bilirubin concentrations (Fig. 4; S2 Table). Rifampicin AUC0-24 at steady state in an exponential 
relation positively correlated (p < 0.01) with t1/2 (Fig. 2), resulting in more pronounced bi-phasic kill-
curves with lower rifampicin concentrations (Fig. 4; S2 Table). Alcohol consumption correlated with 
a slower LAM, resulting in a steeper bacillary kill-curve in sputum in non-alcohol consuming 
patients (Fig. 4; S2 Table). 
Step-wise backward exclusion of isoniazid AUC0-24/MIC, when replacing AUC0-24, as covariate on 
LAM resulted in significant worsening of the model fit on a subset of the patients that had MICs 
reported (S6 Fig.; S3 Table). Step-wise backward exclusion of rifampicin AUC0-24/MIC, when 
replacing AUC0-24, as covariate on t1/2 resulted in a model that did not converge on the same 
subset of patients (S6 Fig.; S3 Table). As per protocol, MIC adjusted PK parameters for 
ethambutol were not evaluated here because neither MIC unadjusted ethambutol AUC0-24 or CMAX 
was significantly correlated with LAM, t1/2 or BETA. 
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Study outcome 
From the static bacteriological treatment response measurements, only SSCC negativity at month 
2 correlated with the likelihood of treatment failure (Table 2). Amongst the pharmacokinetic 
variables, higher isoniazid CMAX, CMAX/MIC and AUC0-24/MIC correlated with treatment success 
(Table 2 and 3). MIC adjusted correlations were stronger when compared to MIC unadjusted 
equivalents (Table 3). 
From the dynamic measurements of treatment response lower model derived LAM and higher 
model derived BETA correlated with failure (p < 0.05) on univariate generalised logistic regression 
(Table 2). Lower LAM was also the only variable from any analysis which associated with TB 
recurrence (p < 0.05) (Table 2 and Table 3). 
Discussion 
CMAX and AUC0-24 estimates for each drug from our PK models were consistent with prior studies in 
African populations.14,19–21 Rifampicin exposure was low, supporting the ongoing case for 
increasing current rifampicin dosages for TB treatment.22 Our PKPD model adequately captured 
the typical bacillary clearance profile and demonstrated that inter-individual variability in antibiotic 
exposure influences treatment response. Early bacterial clearance (characterised by the LAM 
parameter) is faster with higher isoniazid AUC0-24, and bacillary clearance remains rapid, with later 
progression to biphasic decline, with higher rifampicin AUC0-24. These findings are consistent with 
prior reports that the bactericidal effect of isoniazid is enhanced by co-administration with 
rifampicin.6 Although the model structure was rather empirical in it’s description of decreasing 
bactericidal effect over time we did not consider more complex mechanistic PKPD models in order 
to avoid over parameterisation.23 
Elevated serum bilirubin levels have previously been reported with prolongation of isoniazid 
clearance24 and may also correlate with higher exposure of the other two hepatically cleared drugs 
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rifampicin and pyrazinamide. This may be considered as a partial measure of the ability of the body 
to clear these antibiotics. 
Static bacteriological measurements (e.g. sputum smear or culture conversion at month 1 or 2) are 
commonly used to monitor TB treatment response in clinical practice and early phase clinical trials 
and in this study SSCC at month 2 predicted final outcome. Some larger analyses of pooled 
individual patient data have described a similar relationship between month 2 culture results and 
outcome although it has also been noted that correlations are not predictive at individual patient 
level.5,12 
MIC adjusted PK estimates, i.e. AUC0-24/MIC or CMAX/MIC, have been reported as marker of the 
sterilising effect of anti-TB drugs, in line with these findings our PKPD model displayed significant 
correlations in a subset of patients (S3 Table).25 It showed significant correlations between 
isoniazid CMAX, CMAX/MIC and AUC0-24/MIC and treatment success, but not with remaining free of TB 
(Table 3). 
Caution is required when interpreting the findings that isoniazid CMAX correlates separately with 
LAM and with treatment failure; co-linearity between explanatory variables on univariate analyses 
could bias interpretation of the results where isoniazid drives early bacillary clearance from 
sputum, which subsequently correlates with treatment failure. Multivariate regression sometimes 
resolves such issues but was not feasible in this dataset of 95 patients with only 5 failures. Overall, 
delineation of a relationship between antibiotic PK and treatment response remains noteworthy. It 
underlines the role of PK data in explaining trial results and indicates that treatment shortening 
decisions for individual patients requires consideration of antibiotic exposure at steady state, e.g. 2 
months. A large recent meta-analysis seeking to define an “easy-to-treat” patient phenotype 
explicitly commented on the lack of PK data for assessment.26 
Our dynamic, model-derived, parameters of bacterial clearance over the first 8 weeks of treatment 
correlated with treatment failure (LAM and BETA) and recurrence (LAM). These results indicate 
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that the pattern of early bacillary clearance matters. The finding that LAM was the only predictor of 
relapse suggests that efficient use of quantitative longitudinal data at the level of individual patients 
may be preferable to reliance on traditional static measurements of bacteriological response.27 
Our study has limitations. Isolates from recurrent TB infections were not sequenced and 
consequently it remained unclear whether these were re-infections or relapses. Moreover, the 
PKPD model remains descriptive rather than predictive, due to inability to split data into training 
and test batches. Antimicrobial concentration ranges were restricted by standard dosing 
guidelines, yet a concentration-effect relationship could be characterised. However, the model is 
not suitable for extrapolations and dose optimisations due to the absence of a concentration-effect 
relationship that was characterised over an extended concentration range. MIC data were not 
available for every patient and were not available at all for pyrazinamide, hindering efforts to 
account for the variability added to PKPD models by incorporating MIC measurements to indices 
such as AUC0-24/MIC or CMAX/MIC.25 More comprehensive MIC data may be of particular 
importance in global settings where clinical Mtb isolates are less uniformly antibiotic sensitive than 
in Malawi. 
A large pooled individual patient data analysis, ideally with dose escalating studies, would enable 
further characterisation of early bacillary clearance from sputum, and provide improved statistical 
power to correlate early bacillary clearance with treatment failure and recurrence. Nonetheless, the 
data presented here illustrates the value of PKPD and dynamic bacillary clearance modelling 
techniques which could be applicable beyond the drug combination used in this study. More 
extensive use of this approach may improve regimen evaluation in clinical trials. Moreover, it could 
help generate algorithms to assist with clinical decision making for individualised or stratified 
treatment strategies. These algorithms can take into account how well the patient is doing during 
early phases of treatment rather than just baseline measures of on how well the patients is before 
treatment starts. 
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Conclusion 
In conclusion, isoniazid and rifampicin exposure correlate with bacillary clearance from sputum 
during the first 8 weeks of treatment for pulmonary TB and bacillary clearance correlates with 
clinical outcome. A pooled individual patient data analysis is needed to validate the range of early 
pharmacokinetic and sputum bacillary clearance effects which predict treatment failure and 
relapse. 
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Figure legends 
Fig. 1: Simulation based (n=2,000) Visual Predictive Checks (VPCs) for isoniazid (top left), 
rifampicin (top right), pyrazinamide (bottom left) and ethambutol (bottom right). Open circles 
represent observations, solid and dashed black lines represent observed 2.5, 50th and 97.5 
percentiles. Shaded areas represent the 90% confidence intervals around the simulated 2.5, 50 th 
and 97.5 percentiles. 
Fig. 2: Visualisation of PKPD model characteristics. The solid line (A) illustrates monophasic 
bacillary clearance from sputum with a clearance rate represented by LAM. The dashed (B) and 
dotted (C) lines illustrate bi-phasic bacillary clearance trajectories; LAM represents the initial 
clearance rate (faster in B than C line), BETA represents the magnitude of decreased bacillary 
clearance (larger in C than B) and T1/2 represents time it takes to switch from fast to slow killing 
(earlier in B than C). 
Fig. 3: Simulation based (n=2,000) VPCs for the PKPD model. Open circles in the upper panel 
represent observations, solid and dashed black lines represent observed 50th and 97.5 percentiles. 
Shaded areas in the upper panel represent the 90% confidence intervals around the simulated 2.5, 
50th and 97.5 percentiles. The dots and solid line in the lower panel represent the observed 
proportion of samples below the limit of quantification and the shared area represent the 
corresponding 90% confidence interval of proportion samples below limit of quantification produced 
by the model. Bars at the bottom of the lower panel indicate the binning windows. 
Fig. 4: Visualisation pharmacokinetic-pharmacodynamic covariate effects (baseline bilirubin - LAM, 
isoniazid - LAM, rifampicin - t1/2 and alcohol consumption - LAM). High and low exposure refers to 
highest and lowest values in the study population: 1-32 𝜇mol/l, 54.9-515 hrx𝜇mol/l, and 19.9-145 
hrx𝜇mol/l for baseline bilirubin, isoniazid and rifampicin, respectively. 
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Figure 2 
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Figure 3 
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Figure 4 
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